Rolando M. Viani

1.7k total citations · 1 hit paper
45 papers, 937 citations indexed

About

Rolando M. Viani is a scholar working on Infectious Diseases, Epidemiology and Virology. According to data from OpenAlex, Rolando M. Viani has authored 45 papers receiving a total of 937 indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Infectious Diseases, 24 papers in Epidemiology and 13 papers in Virology. Recurrent topics in Rolando M. Viani's work include HIV/AIDS Research and Interventions (21 papers), HIV/AIDS drug development and treatment (20 papers) and HIV Research and Treatment (13 papers). Rolando M. Viani is often cited by papers focused on HIV/AIDS Research and Interventions (21 papers), HIV/AIDS drug development and treatment (20 papers) and HIV Research and Treatment (13 papers). Rolando M. Viani collaborates with scholars based in United States, Mexico and Spain. Rolando M. Viani's co-authors include Stephen A. Spector, Kenneth Bromberg, Maria Rosario G. Araneta, Jaime G. Deville, John S. Bradley, Wayne M. Dankner, Enrique Chacón‐Cruz, Anita Das, Andrew Wiznia and Matteo Bassetti and has published in prestigious journals such as PEDIATRICS, Clinical Infectious Diseases and The Journal of Infectious Diseases.

In The Last Decade

Rolando M. Viani

44 papers receiving 920 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and safety of intramuscular administration of tixagevimab–cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial

2022 127 citations Hugh Montgomery, Richard Hobbs et al. The Lancet Respiratory Medicine profile →

Peers

Countries citing papers authored by Rolando M. Viani

Since Specialization

Citations

This map shows the geographic impact of Rolando M. Viani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rolando M. Viani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rolando M. Viani more than expected).

Fields of papers citing papers by Rolando M. Viani

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rolando M. Viani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rolando M. Viani. The network helps show where Rolando M. Viani may publish in the future.

Co-authorship network of co-authors of Rolando M. Viani

This figure shows the co-authorship network connecting the top 25 collaborators of Rolando M. Viani. A scholar is included among the top collaborators of Rolando M. Viani based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rolando M. Viani. Rolando M. Viani is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Outpatient Treatment with AZD7442 (Tixagevimab/Cilgavimab) Prevented COVID-19 Hospitalizations over 6 Months and Reduced Symptom Progression in the TACKLE Randomized Trial 2023 ·Infectious Diseases and Therapy ·Richard Hobbs, Hugh Montgomery, Francisco Padilla, Jesus Abraham Simón Campos, Kenneth Kim, (unknown), Kelly Padilla, Venkatesh Pilla Reddy, (unknown), Katie Streicher, Alison Templeton, Rolando M. Viani, Eva Johnsson, Gavin Koh, Mark T. Esser	3
2	Efficacy and safety of intramuscular administration of tixagevimab–cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial breakdown → 2022 ·The Lancet Respiratory Medicine ·Hugh Montgomery, Richard Hobbs, Francisco Padilla, Douglas Arbetter, Alison Templeton, (unknown), Kenneth Kim, Jesus Abraham Simón Campos, Rosalinda H. Arends, (unknown), Dennis Brooks, Pedro Garbes, (unknown), Gavin Koh, Kelly Padilla, Katie Streicher, Rolando M. Viani, Vijay Alagappan, Menelas N. Pangalos, Mark T. Esser, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	127
3	1284. Outcomes by Baseline Pathogens and Susceptibility in the STRIVE Phase 2 Trial of Once-Weekly Rezafungin for Treatment of Candidemia and Invasive Candidiasis Compared with Caspofungin 2020 ·Open Forum Infectious Diseases ·George R. Thompson, Juan Pablo Horcajada, Jeffrey B. Locke, Rolando M. Viani, Peter G. Pappas, Mahmoud A. Ghannoum, Taylor Sandison, Àlex Soriano	2
4	Drug-Drug Interactions of Glecaprevir and Pibrentasvir Coadministered With Human Immunodeficiency Virus Antiretrovirals 2019 ·The Journal of Infectious Diseases ·Matthew P. Kosloski, Rajneet K. Oberoi, Stanley Wang, Rolando M. Viani, Armen Asatryan, Beibei Hu, (unknown), Xin Qi, (unknown), Federico Mensa, Jens Kort, Wei Liu	14
5	TURQUOISE-I Part 1b: Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Ribavirin for Hepatitis C Virus Infection in HIV-1 Coinfected Patients on Darunavir 2017 ·The Journal of Infectious Diseases ·David Wyles, Michael S. Saag, Rolando M. Viani, Jacob Lalezari, Oluwatoyin Adeyemi, Laveeza Bhatti, Amit Khatri, Jennifer R. King, Yiran Hu, Roger Trinh, Nancy S. Shulman, Peter Ruane	16
6	Safety, Pharmacokinetics and Efficacy of Dolutegravir in Treatment-experienced HIV-1 Infected Adolescents 2015 ·The Pediatric Infectious Disease Journal ·Rolando M. Viani, Carmelita Alvero, Terry Fenton, Edward P. Acosta, Rohan Hazra, Ellen Townley, (unknown), Sherene Min, Andrew Wiznia	40
7	Use of Integrase Inhibitors in HIV-Infected Children and Adolescents 2015 ·Drugs ·Walter Dehority, Jacobo Abadi, Andrew Wiznia, Rolando M. Viani	15
8	Chest Pain and Shortness of Breath in a Previously Healthy Teenager 2014 ·Journal of the Pediatric Infectious Diseases Society ·Juan D. Chaparro, Elizabeth Murphy, Christopher K. Davis, Rolando M. Viani, Alice Pong	3
9	Parallel Rapid HIV Testing in Pregnant Women at Tijuana General Hospital, Baja California, Mexico 2012 ·AIDS Research and Human Retroviruses ·Rolando M. Viani, Maria Rosario G. Araneta, Stephen A. Spector	8
10	Role of etravirine in the management of treatment-experienced patients with human immunodeficiency virus type 1 2010 ·HIV/AIDS - Research and Palliative Care ·Rolando M. Viani	1
11	Prevalence of Primary HIV‐1 Drug Resistance among Recently Infected Adolescents: A Multicenter Adolescent Medicine Trials Network for HIV/AIDS Interventions Study 2006 ·The Journal of Infectious Diseases ·Rolando M. Viani, Lígia Peralta, Grace M. Aldrovandi, Bill G. Kapogiannis, (unknown), Stephen A. Spector, Yolanda Lie, Jodi Weidler, Michael Bates, Nancy Liu, Craig M. Wilson, (unknown)	45
12	Migration and Risk Factors for HIV Acquisition in Pregnant Women in Baja California, Mexico 2005 ·Journal of the International AIDS Society ·Rolando M. Viani, Maria Rosario G. Araneta, (unknown), Patricia Hubbard, (unknown), Enrique Chacón‐Cruz, Stephen A. Spector	3
13	Perinatal HIV Counseling and Rapid Testing in Tijuana, Baja California, Mexico 2005 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Rolando M. Viani, Maria Rosario G. Araneta, (unknown), Patricia Hubbard, (unknown), Enrique Chacón‐Cruz, Stephen A. Spector	37
14	Migration and risk factors for HIV acquisition in pregnant women in Baja California, Mexico. 2005 ·PubMed ·Rolando M. Viani, Maria Rosario G. Araneta, (unknown), Patricia Hubbard, (unknown), Enrique Chacón‐Cruz, Stephen A. Spector	2
15	Decrease in Hospitalization and Mortality Rates among Children with Perinatally Acquired HIV Type 1 Infection Receiving Highly Active Antiretroviral Therapy 2004 ·Clinical Infectious Diseases ·Rolando M. Viani, Maria Rosario G. Araneta, Jaime G. Deville, Stephen A. Spector	85
16	Sarcoidosis and interstitial nephritis in a child with acquired immunodeficiency syndrome: implications of immune reconstitution syndrome with an indinavir-based regimen 2002 ·The Pediatric Infectious Disease Journal ·Rolando M. Viani	16
17	Gastrostomy Tube Insertion for Improvement of Adherence to Highly Active Antiretroviral Therapy in Pediatric Patients With Human Immunodeficiency Virus 2000 ·PEDIATRICS ·Delane Shingadia, Rolando M. Viani, Ram Yogev, Helen J. Binns, Wayne M. Dankner, Stephen A. Spector, Ellen G. Chadwick	37
18	Pediatric Imported Malaria in New York: Delayed Diagnosis 1999 ·Clinical Pediatrics ·Rolando M. Viani, Kenneth Bromberg	35
19	Human Immunodeficiency Virus Type 1 Phenotypes in Children with Advanced Disease Treated with Long‐Term Zalcitabine 1998 ·The Journal of Infectious Diseases ·Rolando M. Viani, Irene L. Smith, Stephen A. Spector	4
20	POSTOPERATIVE GROUP B STREPTOCOCCAL NECROTIZING FASCIITIS IN A PREVIOUSLY HEALTHY CHILD 1997 ·The Pediatric Infectious Disease Journal ·Rolando M. Viani, (unknown), John S. Bradley	13

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact